Other basic science research pearls include preliminary evidence from a porcine model suggesting botulinum toxin type A facilitates ureteral stone passage and the identification of two different microdeletions in the NELL1 gene on chromosome 11 in men with Peyronie's disease.
Trinity J. Bivalacqua, MD, PhDOther basic science research pearls include preliminary evidence from a porcine model suggesting botulinum toxin type A facilitates ureteral stone passage and the identification of two different microdeletions in the NELL1 gene on chromosome 11 in men with Peyronie's disease. The basic science research take-home messages were presented by Trinity J. Bivalacqua, MD, PhD, of Johns Hopkins University, Baltimore.
Trimodal therapy with neoadjuvant degarelix (Firmagon), cryoablation, and anti-PD-1 therapy extends survival and causes a distant tumor immune response in an immune competent model. Early treatment results from a trial in three men with hormone-naïve oligometastatic prostate cancer are promising.
In an evaluation of BPH samples, elevated aromatase and phosphorylated estrogen receptor levels in patients lacking 5-alpha steroid reductase 2 (SRD5A2) expression suggests an androgenic-to-estrogenic switch in growth signaling. Therefore, targeting the aromatase-estrogen axis may serve as an effective treatment strategy in patients who lack SRD5A2 expression.
Two different microdeletions in the NELL1 gene on chromosome 11 were identified in two of 19 men with Peyronie’s disease, as well as a microdeletion in one man corresponding to part of the CTDSPL gene, both of which are associated with fibrosis. NELL1 overexpression was found to downregulate profibrotic cytokines and upregulate antifibrotic cytokines in tunica albuginea fibroblasts, producing myofibroblasts that increase fibrosis in Peyronie’s disease.
Preliminary evidence suggests that periureteral botulinum toxin type A injection facilitates ureteral stone passage in a porcine model.
Stromal derived factor (SDF)-1 is a small, highly conserved chemokine that binds to CXCR4 and CXCR7. As a potent stem cell chemo-attractant, it may have anti-apoptotic, angiogenic, and neurogenic properties.
Sexual Function/Dysfunction: Mixed results with CCH in Peyronie's
Trauma/Reconstruction/Diversion: New clinical guidelines for stricture
Female Urology: Improvements in OAB therapy
Subscribe to Urology Times to get monthly news from the leading news source for urologists.